Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Giving imatinib mesylate before surgery may shrink the tumor
so that it can be removed.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating
patients with locally advanced gastrointestinal stromal tumor.